Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

News Conference News ESC Heart Failure 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

May 25, 2023

The METEORIC-HF Trial

Podcast TCTMD Talking Points

The METEORIC-HF Trial

May 17, 2023

Beyond the Four Foundational Therapies: Vericiguat and Omecamtiv Mecarbil

Presentation THT 2023

Beyond the Four Foundational Therapies: Vericiguat and Omecamtiv Mecarbil

Presenter: John Teerlink

March 20, 2023

Even When Eligible, Not All Acute HF Patients Get GDMT

News Daily News

Even When Eligible, Not All Acute HF Patients Get GDMT

January 11, 2023

Top Heart Failure News of 2022

News Daily News

Top Heart Failure News of 2022

January 04, 2023

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

News Conference News ESC Heart Failure 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

May 23, 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

April 08, 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presentation ACC 2022

The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic Heart Failure And Reduced Ejection Fraction: METEORIC-HF

Presenter: Michael Felker

April 04, 2022

Omecamtiv Mecarbil--Is It More Effective in Low EFs and Is It Better Than Digoxin?

Presentation THT 2022

Omecamtiv Mecarbil - Is It More Effective in Low EFs

Presenter: John Teerlink

February 01, 2022

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

May 27, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

The GALACTIC-HF Trial

Podcast TCTMD Talking Points

The GALACTIC-HF Trial

April 07, 2021

TCTMD’s Top 10 Most Popular Stories for November 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2020

November 30, 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

News Conference News AHA 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

November 13, 2020

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Industry News

Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

February 25, 2019

News Industry News

Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

October 27, 2015

Video

» Interview

METEORIC-HF: The Effect of Omecamtiv Mecarbil on Exercise Tolerance In Patients with Chronic Heart Failure and Reduced Ejection Fraction

May 4, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.